Company Stock Price of Tenax Therapeutics, Inc. (TENX) Decreases -12.41%

Tenax Therapeutics, Inc. s trend and data analysis indicates that the stock price has dropped -67.79% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -71.75% . Looking at the past 52 week period, the stock price is down -67.63% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Tenax Therapeutics, Inc. has a negative value of -83.09 compared to overall market performance.Based on the Stock Research the Relative Strength Index signal is in over sold territory with a range of 28.81.

Tenax Therapeutics, Inc. (NASDAQ:TENX) has tumbled 12.41% during the past week and has dropped 13.25% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 12.61%. Tenax Therapeutics, Inc. (NASDAQ:TENX) has underperformed the index by 14.24% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Company shares have received an average consensus rating of Hold for the current week Tenax Therapeutics, Inc. (NASDAQ:TENX) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.0198 points or 2.94% at $0.6539 with 1,855,783 shares getting traded. Post opening the session at $0.661, the shares hit an intraday low of $0.63 and an intraday high of $0.7097 and the price was in this range throughout the day. The company has a market cap of $18 million and the number of outstanding shares has been calculated to be 28,119,934 shares. The 52-week high of Tenax Therapeutics, Inc. (NASDAQ:TENX) is $2.94 and the 52-week low is $0.415.

Company has reported several Insider transactions to the SEC, on Nov 29, 2016, Gerald T Proehl (director) purchased 29,882 shares at 1.67 per share price.On Nov 19, 2015, Ronald R Blanck (director) purchased 1,900 shares at 3.20 per share price.

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The Company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, and liquid ventilation and implanted glucose sensing. Tenax Therapeutics Inc., formerly known as Oxygen Biotherapeutics, Inc., is based in United States.


Leave a Reply

Your email address will not be published. Required fields are marked *